Related Experiment Video
Updated: May 25, 2026

07:42
Nerve-sparing Mid-urethral Obstruction (NeMO) in Female Small Rodents
Published on: April 25, 2017
Intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral
Ilker Tinay1, Yiloren Tanidir, Esra Cikler
1Department of Urology, Marmara University School of Medicine, Istanbul, Pendik, Turkey. itinay@marmara.edu.tr
Neurourology and Urodynamics
|January 26, 2012
Summary
Botulinum toxin-A (BoNT-A) injections reduced bladder overactivity and fibrosis in a rat model of partial urethral obstruction. BoNT-A also normalized bladder contractile responses, suggesting a therapeutic role for overactive bladder treatment.
Area of Science:
- Urology
- Pharmacology
- Histomorphology
Background:
- Partial urethral obstruction (PUO) in male rats causes bladder dysfunction, including muscle hypertrophy and increased connective tissue.
- These changes are associated with heightened contractile responses to neurogenic and pharmacological stimuli.
Purpose of the Study:
- To investigate the effects of botulinum toxin-A (BoNT-A) on bladder function and histomorphology in a male rat model of overactive bladder induced by PUO.
Main Methods:
- Male Sprague-Dawley rats underwent PUO to create an overactive bladder model.
- Groups received either saline or BoNT-A injections into the detrusor muscle.
- Bladder function and tissue morphology were assessed 5 and 30 days post-injection.
Main Results:
- BoNT-A significantly reduced PUO-induced bladder tissue changes, including hypertrophy and fibrosis.
- BoNT-A injections normalized bladder contractile responses to electrical field stimulation and carbachol.
- Histological changes were more prominent at 30 days post-saline injection compared to 5 days.
Conclusions:
- Intradetrusor BoNT-A injections effectively mitigate bladder overactivity and associated histopathological changes in a male rat model.
- BoNT-A appears to reduce bladder fibrosis secondary to PUO.
- These findings support BoNT-A as a potential therapeutic agent for managing overactive bladder.

